Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nonrandomized Phase II Hybrid Type 3 Implementation Study: Feasibility and Acceptance of an EHR-embedded Oral Cancer Directed Therapy Toxicity and Adherence Program for Patients With Breast or Gastrointestinal Cancer

NCT03858712 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT03858712
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03858712 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nonrandomized Phase II Hybrid Type 3 Implementation Study: Feasibility and Acceptance of an EHR-embedded Oral Cancer Directed Therapy Toxicity and Adherence Program for Patients With Breast or Gastrointestinal Cancer
Lead sponsor
Dana-Farber Cancer Institute
Phase
Not applicable
Overall status
Completed
Start date
March 13, 2019
Completion date
November 23, 2021
Enrollment
100 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, gastrointestinal cancer, oral cancer directed therapy, oral chemotherapy